cellestia biotech
Cellestia is a bio-pharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway.
cellestia biotech has raised €18M across 2 funding rounds from 2 investors, most recently a round in Aug 2021. Based in Lausanne, Switzerland; founded 2014; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€18M
€18,438,278
Funding rounds
2
Investors
2
distinct backers
Active since
2019-10
latest 2021-08
Funding by year
EUR raised per yearcellestia biotech — funding by year — interactive chart.
Data table
| cellestia biotech — funding by year | |
|---|---|
| 2019 | €18M |
| 2021 | €0 |
Signals
Medium confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-16 | Other | — | SNGLR Capital | View deal → |
| 2019-10-01 | Series B | €18M | FC Capital | View deal → |
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData